Search Results - activity

8 Results

Sort By:

A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors

This invention includes a novel high-throughput assay to identify orthosteric inhibitors blocking the Zika virus NS2B-NS3 protease. Pathogenic flaviviruses, including Zika, require the NS2B-NS3 protease for viral replication. There is currently an unmet need for specific antiviral therapeutics against the Zika virus. Preliminary screening using the...

Published: 7/25/2024 | Inventor(s): Menghang Xia, Ruili Huang, Laura Kramer, Zhong Li, Hongmin Li

Keywords(s): Activity, Antiflaviviral, Compositions, PHARMACEUTICAL, VLXXXX, WIXXXX, WKXXXX, XHXXXX

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, ResearchProducts > Research Equipment, Application > Research Materials

Detection of Retroviruses and HIV-1 Groups -M and -O Discrimination within Clinical Serum Samples

CDC researchers have developed methods for detecting retroviruses within a patient blood sample and discriminating HIV-1 samples within serum specimens. HIV-1 can be genetically classified into two major groups, group M (major) and Group O (outlier) with group O comprising all divergent viruses that do not cluster with group M. The identification of...

Published: 4/8/2024 | Inventor(s): Thomas Folks, Shinji Yamamoto, William Switzer, Walid Heneine

Keywords(s): Activity, assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, Detection, DXXXXX, Methods, OID-NCHHSTP-DHPSE, Reverse, RT, SENSITIVE, TRANSCRIPTASE, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax...

Published: 7/25/2024 | Inventor(s): Dennis Bagarozzi, Anne Boyer, Conrad Quinn, Jason Goldstein

Keywords(s): Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, ResearchProducts > Antibodies, Application > Diagnostics

Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy

Adenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range...

Published: 7/25/2024 | Inventor(s): Dilip Tosh, Kenneth Jacobson

Keywords(s): A3, Activity, ADENOSINE, AGONISTS, Agonists:, Al, ANTAGONISTS, Anticonvulsant, Derivatives, Docking, IB1FXX, IB1XXX, IBXXXX, IXXXXX, NB1EXX, NB1HXX, NB1XXX, NBXXXX, N-Methanocarba, Nucleosides, NXXXXX, PARTIAL, Patent Category - Chemistry, POTENT, RECEPTOR, TRUNCATED

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics

Fast Acting Molecular Probes for Real-Time In Vivo Study of Disease and Therapeutics

This technology is for fast acting molecular probes made from a fluorescent quencher molecule, a fluorophore, an enzyme cleavable oligopeptide (for example targeted by protease) and FDA-approved polyethylene glycol (PEG) as well as associated methods to identify cell activity with these probes. Proteases regulate many cell processes such as inflammation...

Published: 7/25/2024 | Inventor(s): Seulki Lee, Lei Zhu, Xiaoyuan (Shawn) Chen

Keywords(s): AA3AXX, AA3XXX, AAXXXX, ACTING, Activity, AXXXXX, Beacon, fast, IMAGING, Molecular, PROTEASE, THEREOF, USES

Category(s): Collaboration Sought > Collaboration

Methods of Inducing Immune Tolerance Using Immunotoxins

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of rejection response in a patient, including graft-versus-host disease and transplantation of organs, tissues and cells into a host. In a specific embodiment of the invention, the transplant involves pancreatic islet cells. The immunotoxins are targeted via...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Agents, CB1XXX, CBXXXX, Cell, COMBINED, CXXXXX, Dendritic, Graft versus host disease, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, Induce, INDUCING, INHIBIT, IN-VIVO, ISLET, IXXXXX, Maturation, Methds, Method, Methods, Novel, Pancreatic, RELATED, SUPPRESSANT, T, That, TOLERANCE, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Oncology, Application > Therapeutics

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials, Application > Therapeutics

ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation

ADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis....

Published: 7/25/2024 | Inventor(s): Joel Moss

Keywords(s): Activity, Alpha-NAD, Alpha-NADase, ARH3, CB6XXX, CBXXXX, Cell, CXXXXX, Enzyme, Hydrolase:, IB6XXX, IBXXXX, Ihe, IXXXXX, LEVELS, Maintenance, MAMMALIAN, MAY, PAR, PARG-like, Patent Category - Biotechnology, Poly-ADP-ribose, RELEVANT

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Reproductive Health, Application > Diagnostics, Application > Research Materials